Abstract
Toremifene is an anti-estrogen which has been shown to be effective in the treatment of breast cancer, and is thought to be a less uterotrophic agent than tamoxifen. The risk assessment concerning endometrial cancer has been inconclusive because of its rare use up to the mid-1990s. We report a case of an adenosarcoma, which is a very rare type of uterine malignancy, after toremifene treatment for 5 years in a breast cancer patient. After 1 year of toremifene use, the patient had a benign Mullerian adenofibroma. After an additional 4 years of toremifene treatment, the endometrial polypoid lesion was transformed into a Mullerian adenosarcoma. Although toremifene is a promising anti-estrogenic agent in the treatment of breast cancer patients, clinicians should not neglect the possibility of a uterine malignancy.
Original language | English |
---|---|
Pages (from-to) | 269-272 |
Number of pages | 4 |
Journal | Journal of gynecologic oncology |
Volume | 21 |
Issue number | 4 |
DOIs | |
Publication status | Published - 2010 Dec |
Externally published | Yes |
Keywords
- Breast cancer
- Mullerian adenofibroma
- Mullerian adenosarcoma
- Tamoxifen
- Toremifene
ASJC Scopus subject areas
- Oncology
- Obstetrics and Gynaecology